NRX Pharmaceuticals
NRXP
25 hedge funds and large institutions have $2.31M invested in NRX Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
650% more call options, than puts
Call options by funds: $45K | Put options by funds: $6K
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
91% more capital invested
Capital invested by funds: $1.21M → $2.31M (+$1.1M)
39% more funds holding
Funds holding: 18 → 25 (+7)
2.03% more ownership
Funds ownership: 6.64% → 8.67% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$242K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$110K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$58K |
| 4 |
Millennium Management
New York
|
+$37.1K |
| 5 |
Squarepoint
New York
|
+$34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$59.2K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$4.15K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$672 |
| 5 |
HI
Harbour Investments
Madison,
Wisconsin
|
-$79 |
NRXP Hedge Fund Activity: Q4 2024 in Review
25 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q4 2024, worth a combined $2.31M — up 91% from $1.21M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new NRXP positions and 3 closed out — a net gain of 7 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $242K. The largest seller was Sabby Management, exiting entirely with an estimated $59.2K sold.
- 25 institutional investors held NRX Pharmaceuticals (NRXP) as of Q4 2024, up from 18 in Q3 2024.
- Funds reported $2.31M of NRX Pharmaceuticals stock for Q4 2024, up 91% quarter-over-quarter.
- 10 funds opened new NRX Pharmaceuticals positions in Q4 2024 and 3 closed out, a net change of +7 holders.
- The largest NRX Pharmaceuticals buyer in Q4 2024 was AdvisorShares Investments, an estimated $242K added.
- The largest NRX Pharmaceuticals seller in Q4 2024 was Sabby Management, an estimated $59.2K sold.
Based on aggregated 13F filings for Q4 2024.